GNAO1

Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies

Retrieved on: 
Wednesday, March 8, 2023
Perampanel, Catalyst Pharmaceuticals, PIGA, NEU1, PCDH19, Patient, Network, Seizure, POLG2, SYNGAP1, Rare, Neurology, CORAL, GNAO1, Pharmaceutical industry, Catalysis, Epilepsy, SCN1A

The case review from a group of European neurologists treating rare epilepsies working under the framework of NETRE (Network for Therapy in Rare Epilepsies) reports how perampanel (FYCOMPA®) is capable of significantly reducing seizures in patients with epilepsies that result from specific genetic mutations.

Key Points: 
  • The case review from a group of European neurologists treating rare epilepsies working under the framework of NETRE (Network for Therapy in Rare Epilepsies) reports how perampanel (FYCOMPA®) is capable of significantly reducing seizures in patients with epilepsies that result from specific genetic mutations.
  • Out of 137 patients treated with perampanel, 60 patients (43.5%) sustained over 75% reduction in seizure frequency, including 38 (27.5%) with greater than 90% reduction in seizure frequency.
  • High efficacy was consistently observed in certain rare genetic variants, including SCN1A, GNAO1, PIGA, PCDH19, SYNGAP1, POLG1, POLG2, and NEU1.
  • “We look forward to continuing to bring FYCOMPA® to all patients that may benefit from it.”